Santersus AG is a medical technology company focused on developing extracorporeal blood purification therapies for critical-care indications, including sepsis and other inflammation-driven conditions. Its approach centers on selective removal of disease-associated factors from blood plasma using adsorptive devices operated with established apheresis workflows.
The company advances its solutions through preclinical research and multicenter clinical studies and collaborates with healthcare and technology partners to support clinical implementation. Operating at the intersection of biotechnology, biomaterials, and intensive care, Santersus’ work is relevant to hospital-based acute care, immunology, and blood-processing technologies.
None yet. When a new project in the record names Santersus AG as owner, partner or investor, it shows here.
The partnership aims to enhance sepsis treatment by removing NETs from blood, potentially reducing mortality and ICU stays.
